Target expression details
Target's General Information | |||||
---|---|---|---|---|---|
Target ID | T73097 | ||||
Target Name | GMCSFR-alpha (CSF2RA) | ||||
Synonyms | GMR; GM-CSFR; GM-CSF-R-alpha; CSF2RA; CDw116; CD116 antigen | ||||
Target Type | Successful | ||||
Gene Name | CSF2RA | ||||
Biochemical Class | Type I cytokine receptor family | ||||
UniProt ID | CSF2R_HUMAN | ||||
Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
Disease | Acute myelocytic leukemia | ||||
Example drug | Leukemia cancer vaccine | Phase 2 | [1], [2], [3] | ||
Tissue | Bone marrow | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.49 Z-score: -0.88 P-value: 1.10E-05 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Glioma | ||||
Example drug | AFTVac | Phase 2 | [2], [3], [4] | ||
Tissue | Brainstem tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.13 Z-score: -0.28 P-value: 7.80E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Glioma | ||||
Example drug | AFTVac | Phase 2 | [2], [3], [4] | ||
Tissue | White matter | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.44 Z-score: 0.38 P-value: 1.96E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Myeloma | ||||
Example drug | Myeloma cancer vaccine | Phase 2 | [1], [2], [3] | ||
Tissue | Bone marrow | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.14 Z-score: 1.25 P-value: 3.76E-03 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Rectal cancer | ||||
Example drug | Colorectal cancer vaccine | Phase 2 | [2], [3], [5] | ||
Tissue | Rectal colon tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.43 Z-score: -2.15 P-value: 4.48E-03 |
||||
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: -0.25 Z-score: -1.13 P-value: 1.01E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Rheumatoid arthritis | ||||
Example drug | Mavrilimumab | Phase 2 | [2], [3], [6], [7] | ||
Tissue | Synovial tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.16 Z-score: 0.53 P-value: 8.42E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Multiple sclerosis | ||||
Example drug | MOR-103 | Phase 1/2 | [8], [2], [3] | ||
Tissue | Spinal cord | ||||
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 0.06 Z-score: 0.24 P-value: 1.58E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
Target's Expression Profile across Various Tissues of Healthy Individual | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health. | ||||
REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
REF 4 | Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9. | ||||
REF 5 | Clinical pipeline report, company report or official report of Aduro BioTech. | ||||
REF 6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7785). | ||||
REF 7 | Clinical pipeline report, company report or official report of MedImmune (2011). | ||||
REF 8 | ClinicalTrials.gov (NCT01023256) Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.